Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of [...]
NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences in New York in the first half of September [...]
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will deliver two presentations at the World Diabetes [...]
Chairman of HTIT has decades of experience in the diabetes sector in China NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining [...]
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 diabetes; results expected in 4Q 2019; following results Oramed plans to [...]
NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business Development of Oramed, will deliver a corporate presentation, including an [...]
NEW YORK, May 21, 2019 /PRNewswire/ -- ORMD-0801 reaches significant milestone on path to potentially be the first commercial oral insulin capsule for the treatment of Type 2 diabetes Close to 300 patients have now been enrolled. 70% of patients have already completed treatment in the [...]
NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City. [...]
NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]
NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]